Search Clinical Trials in the EU

Duration

16-20 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

81-100 of 112 trials

Lung Cancer Treatment: Adagrasib with Pembrolizumab

We are studying whether adding Adagrasib to standard chemotherapy and Pembrolizumab helps patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The trial will also evaluate safety and quality of life.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)16-20 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementOncology

Hidradenitis Suppurativa: Brensocatib Study

We are testing a new medication, brensocatib, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it is more effective than a placebo in improving symptoms.

Hidradenitis Suppurativa1-2 yearsEfficacy phase (II)16-20 visits Investigational Medicines Cost Reimbursement Partially RemoteDermatology

Kamada-AAT for Inhalation in Alpha-1 Antitrypsin Deficiency

We are studying a new inhalation treatment for adults with congenital Alpha-1 Antitrypsin Deficiency to see if it improves lung function compared to a placebo. The trial also looks at safety and immune responses to the treatment.

Congenital Alpha-1 Antitrypsin Deficiency>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicinePulmonology

Advanced Ovarian Cancer: Niraparib Alone vs. Niraparib with Bevacizumab

We are studying whether combining Niraparib with Bevacizumab improves outcomes for patients receiving chemotherapy for advanced ovarian cancer. This trial aims to see if the combination treatment helps patients live longer without their cancer progressing.

Ovarian CancerPeritoneal CarcinomaFallopian Tube CancerConfirmation phase (III)16-20 visits No Placebo Standard MedicinesOncology

HIV-1 Infection: ART with Long-Acting Antibodies

We are studying whether adding long-acting HIV-specific antibodies to standard treatment can help people with primary HIV-1 infection achieve better control after stopping therapy. This trial will also look at how well participants tolerate the treatment.

HIV-1 Infection>2 yearsEfficacy phase (II)16-20 visits Investigational Medicines Partially RemoteInfectious Diseases

Psoriatic Arthritis: Sonelokimab Treatment Study

We are investigating whether sonelokimab can effectively reduce symptoms in adults with active psoriatic arthritis who have not yet tried biologic treatments. The study will also assess the safety of this new medication compared to a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementDermatologyRheumatology

Crizotinib for Children with Severe Type 2 Neurofibromatosis

We are studying whether crizotinib can help reduce tumor size in children with severe type 2 neurofibromatosis who are not eligible for surgery or radiotherapy. We will also evaluate the safety of this treatment.

Neurofibromatosis Type 21-2 yearsEfficacy phase (II)16-20 visits No Placebo Standard MedicinesNeurologyOncology

ALS Treatment: Masitinib with Riluzole

We are studying whether adding masitinib to Riluzole helps improve outcomes for people with Amyotrophic Lateral Sclerosis. This trial will assess its safety and effectiveness compared to a placebo.

Amyotrophic Lateral Sclerosis6-12 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational MedicinesInternal MedicineNeurology

Multiple System Atrophy: Lu AF82422 Study

We are testing the medication Lu AF82422 to see if it can slow disease progression in people with Multiple System Atrophy. The study will also look at its effects on overall health and quality of life.

Multiple System Atrophy1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Ovarian Cancer: Olaparib and Bevacizumab Study

We are studying how well a new test identifies genetic markers in patients with advanced ovarian cancer and whether combining Olaparib with Bevacizumab improves treatment outcomes. This trial aims to evaluate the safety and effectiveness of this drug combination.

Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer6-12 monthsEfficacy phase (II)16-20 visits No Placebo Standard MedicinesGynecology and ObstetricsOncology

Chronic Obstructive Pulmonary Disease: Tezepelumab Study

We are investigating whether tezepelumab can help adults with moderate to very severe COPD experience fewer flare-ups and improve their lung function and quality of life compared to a placebo.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsConfirmation phase (III)16-20 visits Standard Medicines Cost Reimbursement Partially RemotePulmonology

ALK-Positive Advanced Lung Cancer: NVL-655 vs. Alectinib

We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.

Advanced ALK-positive Non-Small Cell Lung CancerConfirmation phase (III)16-20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Kidney Transplant: Ravulizumab Study

We are testing Ravulizumab in adults at high risk of delayed graft function after kidney transplantation. The goal is to see if it helps improve kidney function and reduces the need for dialysis.

Delayed Graft Function after Kidney Transplantation1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Standard Medicines Partially RemoteInternal MedicineNephrology

ADPKD Treatment: Metformin vs. Tolvaptan

We are studying whether Metformin can effectively slow kidney function decline in adults with Autosomal Dominant Polycystic Kidney Disease compared to Tolvaptan. The trial also examines the safety and impact on kidney size and symptoms.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)16-20 visits No Placebo Standard MedicinesInternal MedicineNephrology

Ulcerative Colitis: MK-7240 Treatment Study

We are studying MK-7240 to see if it helps people with moderately to severely active ulcerative colitis achieve remission. The trial will also evaluate the safety and effectiveness of this new treatment compared to a placebo.

Ulcerative Colitis1-2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterology

Malaria Prevention: Atovaquone-Proguanil Study

We are testing a weekly dose of atovaquone-proguanil to see if it can prevent malaria in healthy volunteers. The study also looks at the safety of the medication and how it behaves in the body.

Malaria6-12 monthsEfficacy phase (II)16-20 visits Investigational MedicinesInfectious Diseases

Bladder Cancer: New Treatment Combination Study

We are investigating a new treatment combining chemotherapy and immunotherapy with radiotherapy for patients with non-metastatic muscle invasive bladder cancer. The goal is to see if this approach improves survival and quality of life after surgery.

Non-Metastatic Muscle Invasive Bladder Cancer1-2 yearsEfficacy phase (II)16-20 visits No Placebo Standard MedicinesOncologyUrology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study

We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.

Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Advanced Clear-Cell Renal Carcinoma: Digital Monitoring with Cabozantinib and Nivolumab

We are studying how digital tracking of symptoms can help adjust treatments for patients with advanced clear-cell renal carcinoma receiving Cabozantinib and Nivolumab. This may improve their overall health and quality of life during treatment.

Kidney Cancer>2 yearsMonitoring phase (IV)16-20 visits No Placebo Standard Medicines Partially RemoteInternal MedicineOncologyUrology

Choline Chloride for Injection in Intestinal Failure

We are studying the safety and effectiveness of Choline Chloride for Injection in adolescents and adults with intestinal failure. This trial compares the treatment to a placebo to see how well it supports patients receiving long-term parenteral nutrition.

Intestinal Failure1-2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visits Post-Trial Drug Access Standard MedicinesGastroenterologyNephrology

Search Clinical Trials in the European Union